Area of research
Infectious Diseases · Virology
Research interest
Research interests include HIV Research and Treatment, HIV/AIDS Research and Interventions, HIV/AIDS drug development and treatment, and HIV-related health complications and treatments.
Comparable Inflammatory and Metabolic Outcomes After Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Continuing Dolutegravir/Lamivudine in Virologically Suppressed Adults With HIV (INSTINCT/GESIDA10918 Study).
A Phase IV, Open-label, Single-Arm, Multicentric Clinical Trial for Evaluation of Human Papillomavirus 9vHPV Vaccine Immunogenicity in Men Who Have Sex With Men With HIV: GeSIDA Study 10 017.
Clarifying INSTINCT: Switching From Dolutegravir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Shows Comparable Inflammatory and Weight Outcomes.
A Review of Doxycycline Post-Exposure Prophylaxis and Its Implications for Antimicrobial Resistance and the Human Microbiome.
Trends in Age-Related Health Outcomes in People with HIV in Spain, 2006-2023.
Neuropsychiatric Tolerability of Long-Acting Cabotegravir and Rilpivirine in People With HIV With Prior INSTI-Related CNS Toxicity: A Real-World Cohort Study.
Closing the PrEP access gap in Europe: a strategic framework for equity and innovation among difficult-to-reach populations.
Effectiveness and tolerability of dolutegravir/lamivudine in virologically suppressed people with HIV at 96 weeks in a multicentre cohort.
Beyond COVID-19 in people with HIV: Specific miRNA expression profile persist after SARS-CoV-2 clearance
Real-world efficacy and tolerability of CAB+RPV LA in women: addressing the gender gap in HIV treatment research.
Long-term effectiveness and tolerability of dolutegravir/lamivudine in treatment-naive people with HIV: an analysis of a multicentre cohort at 96 weeks.
Health-related quality of life in people with HIV from the multicentre CoRIS cohort in Spain: Associated factors and short-term changes over time.
Should we measure quality of life among people with HIV? A multicentre survey of physicians' opinions in Spain.
Two or Three? Clinical and Proteomic Perspectives on Dolutegravir/Lamivudine Versus Bictegravir/Emtricitabine/Tenofovir Alafenamide as Initial HIV Treatment.
Long-Acting Cabotegravir and Rilpivirine in Patients With HIV With Solid Organ Transplantation: A Case Series.
Low-Effort HIV Training in Spanish Primary Care: Long-Term Impact on Testing and Diagnosis
Identification of Inflammation Markers as Novel Potential Predictors of the HIV-DNA Reservoir Size.
Human intestinal microbiome: Role in health and disease.
CD4/CD8 ratio and CD8+ T-cell count as prognostic markers for non-AIDS mortality in people living with HIV. A systematic review and meta-analysis.
Fecal microbiota transplantation alters the proteomic landscape of inflammation in HIV: identifying bacterial drivers.
Acceptability of Long-Acting Injectable Antiretroviral Treatment for HIV Management: Perspectives of Patients and Physicians in Spain.
Feasibility of a selective targeted strategy of HIV testing in emergency departments: a before-after study.
Switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir-based therapy.
All-cause and AIDS-related mortality among people with HIV across Europe from 2001 to 2020: impact of antiretroviral therapy, tuberculosis and regional differences in a multicentre cohort study.
Proteomic snapshot of saliva samples predicts new pathways implicated in SARS-CoV-2 pathogenesis.
Transition times across the HIV care continuum in Spain from 2005 to 2022: a longitudinal cohort study.
High concentrations of Maraviroc do not alter immunological and metabolic parameters of CD4 T cells.
A Phase I/IIa Prospective, Randomized, Open-Label Study on the Safety and Efficacy of Nebulized Liposomal Amphotericin for Invasive Pulmonary Aspergillosis.
Invasive group A Streptococcus infection (Streptococcus pyogenes): Current situation in Spain.
Transmitted Drug Resistance and HIV Diversity Among Adolescents Newly Diagnosed With HIV in Spain.